Editas Medicine, Inc. operates as a clinical-stage biotechnology company dedicated to translating the power of CRISPR gene editing into a new class of precision genomic medicines. The company's research and development efforts are primarily focused on in vivo gene editing, targeting diseases such as hemoglobinopathies (including sickle cell disease and beta-thalassemia) and hyperlipidemia. Editas utilizes its proprietary CRISPR/Cas9 and CRISPR/Cas12a (Cpf1) platforms to repair broken genes at the DNA level. Geographically headquartered in Cambridge, Massachusetts, with additional facilities in Boulder, Colorado, the company collaborates with other pharmaceutical firms to advance cellular therapies in oncology and neurological diseases. Its competitive position is anchored by its foundational intellectual property and its pioneering role in the clinical application of CRISPR technologies.
